Memorial Sloan Kettering Cancer Center’s highly anticipated report on Zantac cancer has finally been completed. Its findings were presented in a research letter published by the Journal of American Medicine on January 29, 2021.
Sloan Kettering Zantac Cancer Report Welcomed by Healthcare Experts
While completion and publication of the Zantac / Ranitidine cancer report was expected nearly a year prior, issues pertaining to the COVID-19 pandemic may have delayed its release.
Nevertheless, the Sloan Kettering study remains highly relevant to current issues surrounding drug safety. In addition, the Zantac cancer report is expected to play a pivotal role in the next stage of lawsuits seeking compensation for antacid users.
For additional information on our Zantac cancer lawyers, click here.
Heartburn Drug Caused Tumor?
At its outset, the Sloan Kettering report acknowledges the presence of NDMA in pharmaceuticals containing ranitidine. NDMA is known to cause cancer in humans.
In fact, it was the detection of NDMA in products containing ranitidine that prompted the FDA to investigate Zantac in 2019. The FDA ultimately sought and obtained removal of Zantac from the U.S. market place in April 2020.
Memorial Sloan Kettering Cancer Center Details Zantac / Ranitidine NDMA Byproduct
Sloan Kettering’s Zantac cancer report accepts the scientific possibility that, under the right circumstances, NDMA could be produced as a byproduct of chemical change occurring within antacid tablets.
Further, Sloan Kettering Cancer Center highlights the various physiologic gastric states that Zantac could encounter. Moreover, their study analyzed the risk of NDMA production under each of those simulated conditions. To access Sloan Kettering’s ranitidine information webpage, click here.
Increased Rate of NDMA Production Reported at Certain Gastric States
Perhaps not surprising, the Sloan Kettering Zantac cancer report identified NDMA production at precise suboptimal conditions.
Specifically, the research focused on NDMA creation at certain temperature and humidity levels at which Zantac may be stored. These results underscore the necessity of storing your medication in a cool, dry place.
In addition, the research analyzed NDMA formation at pH levels encountered in the human stomach. That NDMA could then cause tumor growth or other cell mutations and cancer growth.
